NOW APPROVED IN Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL)
24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of
BRUKINSA: SUPERIOR
EFFICACY ACROSS LINES
OF
THERAPY IN CLL1,3
- Superior PFS vs BR in 1L
- Superior PFS and ORR vs ibrutinib in 2L
- Low rates of cardiac events, including afib/flutter
BRUKINSA was designed to meet the challenges of BTK inhibition,
including in adult patients with CLL/SLL1
EFFICACY DEMONSTRATED
ACROSS LINES OF THERAPY
EFFICACY IN 2 GLOBAL PHASE 3 TRIALS
CONSISTENT EFFICACY IN AN
ADDITIONAL PHASE 1/2 TRIAL






EFFICACY IN 2 GLOBAL PHASE 3 TRIALS


CONSISTENT EFFICACY IN AN
ADDITIONAL PHASE 1/2 TRIAL

SEQUOIA (Study 304) assessed the efficacy and safety of BRUKINSA in 589 adult patients with treatment-naïve CLL/SLL. SEQUOIA was a global Phase 3, randomized, open-label, multicenter study.1
ALPINE (Study 305) assessed the efficacy and safety of BRUKINSA in 652 adult patients with relapsed/refractory CLL/SLL who had received ≥1 prior systemic therapy. ALPINE was a global Phase 3, randomized, open-label, multicenter trial.1,3
AU-003 assessed the long-term safety and efficacy of BRUKINSA in 123 adult patients with treatment-naïve or relapsed/refractory CLL/SLL. AU-003 was a global supportive Phase 1/2, open-label, multicenter, single-arm trial.6
1L=first line; 2L=second line; afib=atrial fibrillation; BR=bendamustine+rituximab; BTK=Bruton's tyrosine kinase; CI=confidence interval; CLL=chronic lymphocytic leukemia; HR=hazard ratio; ORR=overall response rate; PBMCs=peripheral blood mononuclear cells; PFS=progression-free survival; SLL=small lymphocytic lymphoma.
CONSISTENTLY LOW RATES OF AFIB/FLUTTER AND
DISCONTINUATION ACROSS TRIALS
CONSISTENCY IN 2 GLOBAL PHASE 3 TRIALS
CONSISTENCY IN AN ADDITIONAL
TRIAL (Phase 1/2)






CONSISTENCY IN 2 GLOBAL PHASE 3 TRIALS


CONSISTENCY IN AN ADDITIONAL
TRIAL (Phase 1/2)

1L=first line; 2L=second line; AE=adverse event; afib=atrial fibrillation; BR=bendamustine+rituximab.